A Radical Treatment for Insulin Pricing

This article discusses the persistent high costs of insulin in the United States and evaluates the limitations of current biosimilar pricing strategies. It explores the market failure driven by intermediaries such as PBMs, insurers, and manufacturers who benefit from inflated list prices. The article highlights Civica, a nonprofit organization aiming to offer biosimilar insulins at transparent, significantly reduced prices starting in 2024. The case is made for disruptive business models as essential to reforming insulin affordability.

This article discusses the persistent high costs of insulin in the United States and evaluates the limitations of current biosimilar pricing strategies. It explores the market failure driven by intermediaries such as PBMs, insurers, and manufacturers who benefit from inflated list prices. The article highlights Civica, a nonprofit organization aiming to offer biosimilar insulins at transparent, significantly reduced prices starting in 2024. The case is made for disruptive business models as essential to reforming insulin affordability.